Jabbour, E., Faderl, S., Sasaki, K., Kadia, T., Daver, N., Pemmaraju, N., Patel, K., Khoury, J. D., Bueso‐Ramos, C., Bohannan, Z., Ravandi, F., Borthakur, G., Verstovsek, S., Miller, D., Maduike, R., Hosing, C., Kantarjian, H. M., & Garcia‐Manero, G. (2017). phase 2 study of low‐dose clofarabine plus cytarabine for patients with higher‐risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer, 123(4), 629–637. http://access.bl.uk/ark:/81055/vdc_100041488805.0x000053